Isotechnika has announced the 24-week data for the company's Canadian Phase III psoriasis trial for its lead immunosuppressive drug, ISA247.
All primary and secondary efficacy endpoints were achieved at 24 weeks, and efficacy endpoints were achieved with minimal side-effects. In mid- and low-dose groups, continued improvement in PASI (Psoriasis Area and Severity Index) scores were observed from 12 to 24 weeks. No clinically significant differences in mean serum creatinine and glomerular filtration rate were observed amongst the four treatment groups at 24 weeks.
ISA247 is an immunosuppressant currently in an extension protocol of a Canadian Phase III human clinical trial for the treatment of moderate-to-severe psoriasis. In addition, ISA247 has successfully completed a Phase IIa trial for kidney transplantation.